The quarter’s financial print was slightly below expectations. Relay reported a $0.41 per-share loss versus published consensus of roughly $0.40 and revenue of $0.35 million versus an expectation near $0.89 million, making the headline result a narrow miss rather than a beat.
| Metric | Q2 2026 | Q2 2025 | Published expectation |
|---|---|---|---|
| Revenue | $0.35 million (Income Statement) | $0.68 million (Income Statement) | ~$0.89 million |
| Net loss | $83.7 million (Income Statement) | $70.4 million (Income Statement) | — |
| Net loss per share | $0.41 loss (Income Statement) | $0.41 loss (Income Statement) | ~$0.40 loss |
| R&D expense | $76.5 million (Income Statement) | $63.9 million (Income Statement) | — |
| Cash, cash equivalents and investments | $910.9 million (Balance Sheet Data) | $554.5 million at Dec. 31, 2025 (Balance Sheet Data) | — |
The more important update was strategic clarity in frontline breast cancer. Relay selected zovegalisib plus atirmociclib and endocrine therapy as its go-forward triplet, with a Phase 3 trial in endocrine-sensitive first-line patients targeted for early 2027, subject to regulatory feedback. Pfizer’s supply agreement reduces execution friction, while Relay retains global rights to zovegalisib (Front-line Breast Cancer).
The clinical evidence is encouraging but still early. The triplet produced a 44% response rate in heavily pretreated, median third-line patients, with adverse events described as consistent with the individual drugs; however, the doses were not optimized and the data come from a small early-stage setting, so they do not yet establish Phase 3 success (Front-line Breast Cancer). In vascular anomalies, 60% of patients achieved a volumetric response at 12 weeks and nearly all reported symptom improvement, but this remains an interim Phase 1/2 signal rather than confirmatory evidence (Vascular Anomalies).
The cash position materially lowers near-term financing risk, but was largely explainable by the May offering. Cash and investments rose to $910.9 million from $642.1 million at March 31, 2026, primarily because Relay raised approximately $316 million in gross proceeds; management now projects funding into 2029 (Cash, Cash Equivalents and Investments). That is supportive, but the balance-sheet improvement is not wholly new information because the financing had already been announced.
Net read: strategically constructive, financially modestly disappointing. The new triplet direction, planned first-line trial, and early vascular-anomaly data improve visibility around the pipeline, while continued Phase 3 execution preserves the main value driver (Corporate Highlights). Against expectations, though, the quarter itself was a small financial miss and the clinical evidence remains preliminary, leaving the overall filing mixed rather than clearly positive.
Read the original 8-K on SEC EDGAR ↗